{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:47:10Z","timestamp":1782719230514,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate late genitourinary (GU) toxicities on receiving intensity-modulated radiation therapy (IMRT) in patients with prostate cancer (PCa) who had a history of invasive interventions for the prostate or bladder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Among patients who received IMRT for PCa at our institution between August 2000 and December 2022, clinical outcomes among those with a history of invasive interventions for the prostate or bladder were retrospectively analyzed. Cumulative incidence rates of late\u2009\u2265\u2009grade 2 and\u2009\u2265\u2009grade 3 GU and gastrointestinal toxicities, and rates of overall survival (OS) and biochemical failure-free survival (BFFS) were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 32 consecutive patients were analyzed, among whom 28 received conventional fractionated IMRT with a median dose of 74\u00a0Gy in 37 fractions, and 4 underwent moderately hypo-fractionated IMRT with a median dose of 54\u00a0Gy in 15 fractions. The median follow-up period was 77.3\u00a0months after IMRT. Cumulative incidence rates of\u2009\u2265\u2009grade 2 and\u2009\u2265\u2009grade 3 GU toxicities were 20.7 and 4.3% at 5\u00a0years, and 26.4 and 4.3% at 8\u00a0years, respectively. More than 10\u00a0years after IMRT, 18.8% of patients developed\u2009\u2265\u2009grade 2 GU toxicities. OS and BFFS rates were 89.5 and 76.0% at 5\u00a0years, and 89.5 and 60.7% at 8\u00a0years, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prostate IMRT for patients with a history of invasive interventions for the prostate or bladder was considered a safe and feasible treatment option, although the incidence of late GU toxicities was relatively high. Long-term follow-up with close attention to the detection of GU toxicities is recommended for such a population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Secondary abstract<\/jats:title>\n                    <jats:p>Clinical outcomes of IMRT in 32 patients with prostate cancer and a history of invasive interventions for the prostate or bladder were retrospectively analyzed. Although the incidence of late genitourinary toxicities was relatively high, prostate IMRT was considered a safe and feasible treatment option for such a population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11604-026-01969-9","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T04:11:03Z","timestamp":1773461463000},"page":"1283-1289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Late urinary toxicity after prostate intensity-modulated radiation therapy for patients with history of invasive interventions for prostate or bladder"],"prefix":"10.1007","volume":"44","author":[{"given":"Koichi","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihito","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Masui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Sumiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8135-8746","authenticated-orcid":false,"given":"Takashi","family":"Mizowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"1969_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1969_CR2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1007\/s10147-024-02575-3","volume":"29","author":"T Sasaki","year":"2024","unstructured":"Sasaki T, Higashi T, Inoue T. Urological cancer statistics on incidence from 1975 to 2019 and mortality from 1958 to 2022 in Japan. Int J Clin Oncol. 2024;29:1088\u201395.","journal-title":"Int J Clin Oncol"},{"key":"1969_CR3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10147-024-02517-z","volume":"29","author":"K Nakamura","year":"2024","unstructured":"Nakamura K, Nihei K, Saito Y, Shikama N, Noda SE, Hara R, et al. A Japanese multi-institutional phase II study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer. Int J Clin Oncol. 2024;29:847\u201352.","journal-title":"Int J Clin Oncol"},{"key":"1969_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.ijrobp.2024.11.010","volume":"121","author":"W Fukuokaya","year":"2025","unstructured":"Fukuokaya W, Miki K, Aoki M, Takahashi H, Saito S, Yorozu A, et al. Ten-year outcomes of a phase 3, multicenter, randomized controlled trial (SHIP0804) with 3-month neoadjuvant androgen deprivation prior to (125)i-seed transperineal prostate brachytherapy followed by nil versus 9-month adjuvant hormonal therapy in patients with intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2025;121:875\u201384.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1969_CR5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ijrobp.2023.08.046","volume":"118","author":"A Yorozu","year":"2024","unstructured":"Yorozu A, Namiki M, Saito S, Egawa S, Yaegashi H, Konaka H, et al. Trimodality therapy with Iodine-125 brachytherapy, external beam radiation therapy, and short- or long-term androgen deprivation therapy for high-risk localized prostate cancer: results of a multicenter, randomized phase 3 trial (TRIP\/TRIGU0907). Int J Radiat Oncol Biol Phys. 2024;118:390\u2013401.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1969_CR6","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","volume":"43","author":"DJ Brenner","year":"1999","unstructured":"Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095\u2013101.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1969_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.juro.2012.08.091","volume":"189","author":"S Kim","year":"2013","unstructured":"Kim S, Moore DF, Shih W, Lin Y, Li H, Shao YH, et al. Severe genitourinary toxicity following radiation therapy for prostate cancer--how long does it last? J Urol. 2013;189:116\u201321.","journal-title":"J Urol"},{"key":"1969_CR8","first-page":"31","volume":"6","author":"H Inokuchi","year":"2017","unstructured":"Inokuchi H, Mizowaki T, Norihisa Y, Takayama K, Ikeda I, Nakamura K, et al. Correlation between urinary dose and delayed radiation cystitis after 78 Gy intensity-modulated radiotherapy for high-risk prostate cancer: A 10-year follow-up study of genitourinary toxicity in clinical practice. Clin Transl Radiat Oncol. 2017;6:31\u20136.","journal-title":"Clin Transl Radiat Oncol"},{"key":"1969_CR9","doi-asserted-by":"crossref","unstructured":"Takeda K, Umezawa R, Ishikawa Y, Yamamoto T, Takahashi N, Takeda K, et al. Clinical predictors of severe late urinary toxicity after curative intensity-modulated radiation therapy for localized prostate cancer. J Radiat Res. 2021.","DOI":"10.1093\/jrr\/rrab074"},{"key":"1969_CR10","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.ijrobp.2009.06.078","volume":"77","author":"K Devisetty","year":"2010","unstructured":"Devisetty K, Zorn KC, Katz MH, Jani AB, Liauw SL. External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity. Int J Radiat Oncol Biol Phys. 2010;77:1060\u20135.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1969_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13014-018-1149-0","volume":"13","author":"M Guilhen","year":"2018","unstructured":"Guilhen M, Hennequin C, Ouzaid I, Fumagalli I, Martin V, Guillerm S, et al. Urinary function and quality of life after radiotherapy for prostate cancer in patients with prior history of surgical treatment for benign prostatic hyperplasia. Radiat Oncol. 2018;13:209.","journal-title":"Radiat Oncol"},{"key":"1969_CR12","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ijrobp.2024.06.003","volume":"120","author":"M Singh","year":"2024","unstructured":"Singh M, Maitre P, Krishnan A, Adsul K, Mini Sreekumar S, Chauhan H, et al. Late urinary toxicity after extreme or moderate hypofractionated prostate radiation therapy in patients with prior transurethral resection of prostate. Int J Radiat Oncol Biol Phys. 2024;120:1011\u201320.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1969_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/COC.0b013e3182546821","volume":"37","author":"H Ishiyama","year":"2014","unstructured":"Ishiyama H, Hirayama T, Jhaveri P, Satoh T, Paulino AC, Xu B, et al. Is there an increase in genitourinary toxicity in patients treated with transurethral resection of the prostate and radiotherapy? A systematic review. Am J Clin Oncol. 2014;37:297\u2013304.","journal-title":"Am J Clin Oncol"},{"key":"1969_CR14","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s10147-019-01478-y","volume":"24","author":"R Aizawa","year":"2019","unstructured":"Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, et al. Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation. Int J Clin Oncol. 2019;24:1247\u201355.","journal-title":"Int J Clin Oncol"},{"key":"1969_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10147-023-02456-1","volume":"29","author":"R Aizawa","year":"2024","unstructured":"Aizawa R, Inokuchi H, Ikeda I, Nakamura K, Ogata T, Akamatsu S, et al. Impact of prostate position-based image-guidance in intensity-modulated radiation therapy for localized prostate cancer. Int J Clin Oncol. 2024;29:325\u201332.","journal-title":"Int J Clin Oncol"},{"key":"1969_CR16","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/jrr\/rry060","volume":"59","author":"K Nakamura","year":"2018","unstructured":"Nakamura K, Ikeda I, Inokuchi H, Takayama K, Inoue T, Kamba T, et al. A pilot study of highly hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer. J Radiat Res. 2018;59:656\u201363.","journal-title":"J Radiat Res"},{"key":"1969_CR17","doi-asserted-by":"publisher","first-page":"7859","DOI":"10.1002\/cam4.5554","volume":"12","author":"K Nakamura","year":"2023","unstructured":"Nakamura K, Norihisa Y, Ikeda I, Inokuchi H, Aizawa R, Kamoto T, et al. Ten-year outcomes of whole-pelvic intensity-modulated radiation therapy for prostate cancer with regional lymph node metastasis. Cancer Med. 2023;12:7859\u201367.","journal-title":"Cancer Med"},{"key":"1969_CR18","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/cas.16429","volume":"116","author":"R Aizawa","year":"2025","unstructured":"Aizawa R, Ogata T, Goto T, Nakamura K, Takayama K, Ashida R, et al. Highly hypofractionated biaxially rotational dynamic radiation therapy (BROAD-RT) for high-risk prostate cancer. Cancer Sci. 2025;116:1004\u201311.","journal-title":"Cancer Sci"},{"key":"1969_CR19","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s10147-021-02002-x","volume":"26","author":"R Aizawa","year":"2021","unstructured":"Aizawa R, Nakamura K, Norihisa Y, Ogata T, Inoue T, Yamasaki T, et al. Long-term safety of high-dose whole pelvic IMRT for high-risk localized prostate cancer through 10-year follow-up. Int J Clin Oncol. 2021;26:2113\u201322.","journal-title":"Int J Clin Oncol"},{"key":"1969_CR20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s10147-019-01596-7","volume":"25","author":"R Aizawa","year":"2020","unstructured":"Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, et al. Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy. Int J Clin Oncol. 2020;25:713\u20139.","journal-title":"Int J Clin Oncol"},{"key":"1969_CR21","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.21873\/anticanres.16538","volume":"43","author":"T Ogata","year":"2023","unstructured":"Ogata T, Aizawa R, Nakamura K, Kobayashi T, Akamatsu S, Nakamura E, et al. Impact of long-term adjuvant hormonal therapy in high-dose IMRT for unfavorable locally advanced prostate cancer. Anticancer Res. 2023;43:3589\u201396.","journal-title":"Anticancer Res"},{"key":"1969_CR22","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach 3rd","year":"2006","unstructured":"Roach M 3rd, Hanks G, Thames H Jr., Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1969_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1969_CR24","unstructured":"National Comprehensive Cancer network (NCCN). Prostate cancer (version 2.2026). National Comprehensive Cancer Network; Available: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf [Accessed 14 November 2026]."},{"key":"1969_CR25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1590\/S1677-55382007000500006","volume":"33","author":"RA Nakamura","year":"2007","unstructured":"Nakamura RA, Monti CR, Castilho LN, Trevisan FA, Valim AC, Reinato JA. Prognostic factors for late urinary toxicity grade 2-3 after conformal radiation therapy on patients with prostate cancer. Int Braz J Urol. 2007;33:652\u20139 (discussion 60-1).","journal-title":"Int Braz J Urol"},{"key":"1969_CR26","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ijrobp.2004.08.014","volume":"61","author":"DJ Demanes","year":"2005","unstructured":"Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy\u2019s 10-year results. Int J Radiat Oncol Biol Phys. 2005;61:1306\u201316.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1969_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00555","volume":"10","author":"A Pepin","year":"2020","unstructured":"Pepin A, Aghdam N, Shah S, Kataria S, Tsou H Jr., Datta S, et al. Urinary morbidity in men treated with stereotactic body radiation therapy (SBRT) for localized prostate cancer following transurethral resection of the prostate (TURP). Front Oncol. 2020;10:555.","journal-title":"Front Oncol"},{"key":"1969_CR28","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/j.clon.2021.08.010","volume":"34","author":"S Maulik","year":"2022","unstructured":"Maulik S, Arunsingh M, Arun B, Prasath S, Mallick I. Moderately hypofractionated radiotherapy and androgen deprivation therapy for high-risk localised prostate cancer: predictors of long-term biochemical control and toxicity. Clin Oncol (R Coll Radiol). 2022;34:e52\u201360.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1969_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-59406-8","volume":"14","author":"T Perennec","year":"2024","unstructured":"Perennec T, Roge M, Hetet JF, Colls P, Guimas V, Rio E, et al. Salvage prostate intensity modulated radiation therapy after cryotherapy failure. Sci Rep. 2024;14:9148.","journal-title":"Sci Rep"},{"key":"1969_CR30","doi-asserted-by":"publisher","first-page":"1028858","DOI":"10.3389\/fonc.2022.1028858","volume":"12","author":"V Di Lalla","year":"2022","unstructured":"Di Lalla V, Elakshar S, Anidjar M, Tolba M, Hassan T, Bahoric B, et al. Salvage external beam radiotherapy after HIFU failure in localized prostate cancer: A single institution experience. Front Oncol. 2022;12:1028858.","journal-title":"Front Oncol"},{"key":"1969_CR31","volume":"6","author":"BS Laughlin","year":"2023","unstructured":"Laughlin BS, Narang GL, Cheney SM, Humphreys MR, Vargas CE, Keole SR, et al. Toxicity and outcomes after external beam irradiation for prostate cancer in patients with prior holmium laser enucleation of the prostate: Early experience. Cancer Rep (Hoboken). 2023;6:e1672.","journal-title":"Cancer Rep (Hoboken)"},{"key":"1969_CR32","doi-asserted-by":"publisher","first-page":"e392","DOI":"10.1016\/j.clon.2022.05.021","volume":"34","author":"C Huck","year":"2022","unstructured":"Huck C, Achard V, Zilli T. Surgical treatments of benign prostatic hyperplasia and prostate cancer stereotactic radiotherapy: impact on long-term genitourinary toxicity. Clin Oncol (R Coll Radiol). 2022;34:e392\u20139.","journal-title":"Clin Oncol (R Coll Radiol)"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-01969-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-026-01969-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-01969-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:16:16Z","timestamp":1782717376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-026-01969-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1969"],"URL":"https:\/\/doi.org\/10.1007\/s11604-026-01969-9","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}